U.S. Markets open in 6 hrs 6 mins

Exploring JNJ’s Key Oncology Assets in the First Quarter

Margaret Patrick
Exploring JNJ’s Key Oncology Assets in the First Quarter

Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Imbruvica’s trendsIn the first quarter, Johnson & Johnson (JNJ) and AbbVie’s (ABBV) Imbruvica reported 40% YoY (year-over-year) growth in